← Database
M&A

UNIVERSITY COMPOUNDING PHARMACY (UCP)

Acquired by

FAGRON

UNITED STATES Life Sciences EV [1m USD - 100m USD] 01/2026

Target

UNIVERSITY COMPOUNDING PHARMACY (UCP)

Acquirer

FAGRON

Context

Fagron acquired 100% of University Compounding Pharmacy for an Enterprise granting to Fagron a stronghold in California (a high-barrier market) and adds complementary therapeutic expertise (Urology) to its existing US portfolio (which includes Anazao). Fagron expects to realize significant synergies over the next 18-24 months by integrating UCP into its national platform.

The transaction values UNIVERSITY COMPOUNDING PHARMACY (UCP) at an EV/Revenue multiple of LOGIN.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Based in San Diego, UCP is a specialized 503A compounding pharmacy. Unlike 503B facilities (which manufacture in bulk for hospitals), 503A pharmacies prepare patient-specific medications prescribed by doctors. UCP has built a strong niche in the "Health & Wellness" segment, with specific leadership in Urology (e.g., erectile dysfunction treatments) and Hormone Replacement Therapy (HRT). It operates in California, a state with notoriously strict pharmacy regulations, making its license and clean compliance record a valuable asset. The company generates annual revenues of around $25 million.

Ent. Value

LOGIN

Equity Value

LOGIN

Multiples Analysis

EV / Revenue

LOGIN

EV / EBITDA

LOGIN

EV / EBIT

LOGIN

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2025
LOGIN
LOGIN
LOGIN
2024
LOGIN
LOGIN
LOGIN

Other operations with UNIVERSITY COMPOUNDING PHARMACY (UCP)

mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.